MétaCan
Menu
← Back to cohort
Record W4410232452 · doi:10.1093/rap/rkaf053

Onco-rheumatology: from rags to riches, a transdisciplinary evolution

2025· editorial· en· W4410232452 on OpenAlexaff
Daniela Marotto, Canio Martinelli, Patrizia Maiorano, Antonella Fioravanti, Patrizia Amato, Giovanni Baglìo, Graziella Calugi, Andrea Fiorillo, Tindara Franchina, Francesca Gimigliano, Giovanni Iolascon, Maria Cristina Maggio, Luciano Mutti, Luigi Pirtoli

Bibliographic record

VenueRheumatology Advances in Practice · 2025
Typeeditorial
Languageen
FieldMedicine
TopicRheumatoid Arthritis Research and Therapies
Canadian institutionsSurgical Specialties (Canada)
Fundersnot available
KeywordsRheumatologyMedicineInternal medicineDisciplineFamily medicineLawPolitical science

Abstract

fetched live from OpenAlex

With ongoing advancements in medicine, patient management has become increasingly complex, especially when multiple conditions intersect. The need for integrated, transdisciplinary approaches has never been more critical. This complexity arises not only from the proliferation of targeted therapies, but also from the interplay of multilevel interactions among different organ systems, patient-specific variables and evolving risk factors. In such a non-linear landscape, ‘single-disease’ models often prove inadequate, as they fail to capture the full scope of intertwined pathophysiological processes. Indeed, the World Health Organization together with the National Institutes of Health and the Italian Ministry of Health advocate for considering the full scope of a patient’s life, circumstances and evolving needs rather than the single disease. Onco-rheumatology, the intersection of oncology and rheumatology, represents a significant complex scientific and clinical challenge that requires urgent attention as central questions arise: How can we best manage patients facing overlapping cancer and autoimmune conditions? What are the consequences of treating cancer in the presence of autoimmune diseases, or vice versa? In this rapidly evolving landscape, the EULAR has attempted to address these challenges, but clear data are lacking [1]. The transdisciplinary approach is the solution that emerges from rheumatology’s own history in the resolution of systemic sclerosis [2]. The relationship between cancer and rheumatic diseases has been recognized since 1944, with >9000 articles on PubMed exploring the topic, but an integrated onco-rheumatologic model appears in only one paper. Why does onco-rheumatology matter? The urgency arises from the growing number of patients with autoimmune diseases at higher risk of cancer [3] and the uncertainty about whether new cancer treatments may worsen rheumatic conditions [4]. In addition to the unresolved issues—such as the management of rheumatologic paraneoplastic syndromes and patients undergoing androgen- or oestrogen-suppressive therapy—new challenges have emerged with the introduction of immune checkpoint inhibitors (ICIs). These therapies have revolutionized the treatment of certain malignancies, notably metastatic melanoma and advanced non–small-cell lung cancer, by significantly improving overall survival. Building on these successes, emerging immunotherapeutic strategies such as bispecific T cell engagers (BiTEs) are now under investigation for other tumour types, potentially further expanding therapeutic options. However, ICIs also cause immune-related adverse effects (irAEs) in up to 80% of patients [5]. Within this broader category, rheumatic irAEs (Rh-irAEs) appear in an estimated 5–10% of patients, and while severe cases such as myositis or myocarditis are rare (<1% of patients), their mortality rates can climb to 22%. These data are also questionable due to the current lack of clarity. First, Rh-irAEs are overshadowed by life-threatening visceral or endocrine irAEs. Second, non-specific symptoms (e.g. arthralgias, myalgias) are misattributed to the underlying malignancy. Third, many Rh-irAEs lack consistent autoantibody markers and exhibit delayed onset. Moreover, prospective trials commonly exclude patients with pre-existing rheumatic disease, and retrospective or real-world studies often group Rh-irAEs together with broader irAEs [4, 5]. Overlapping classifications—for instance, when myositis or myocarditis is labelled simply as an irAE—compound these challenges. Standardized diagnostic criteria and robust pharmacovigilance with a more systematic strategy are key to enable earlier rheumatologic consultation and tailored treatment, which may include NSAIDs, glucocorticoids, conventional DMARDs, biologic DMARDs or, in certain cases, discontinuation of ICIs [4, 5]. Although epidemiological data indicate higher rates of malignancy in systemic sclerosis, RA, lupus erythematosus and SS [3], no standardized screening protocols currently exist for these populations. Current evidence supports closer surveillance for skin and cervical malignancies in patients receiving immunosuppressive therapy [6], but formal guidelines for lymphoma screening or other cancers remain unclear. This gap underscores the need for ongoing collaboration among rheumatologists, oncologists and primary care teams to establish evidence-based screening strategies. No studies have evaluated tumour marker–based screening for early neoplasm detection in RA. Innovative approaches such as a multimarker panel (CA125, PSA, CEA, CA19-9, AFP, CA15-3, CA72-4, CYFRA 21-1) combined with artificial intelligence (OncoSeek) have shown 67% accuracy in predicting various cancers in healthy individuals [7]. Another critical issue is the lack of robust data on the impact of rheumatologic therapies on cancer risk. MTX was once believed to elevate cancer risk but no longer appears conclusively linked to higher malignancy rates, biologic DMARDs are similarly unassociated with tumour recurrence or development and rituximab is even recommended for patients with a history of lymphoproliferative disorders. However, concerns have been raised regarding Janus kinase (JAK) inhibitors. It is true that the introduction of JAK inhibitors has further expanded the options available to rheumatologists, but a recent randomized controlled trial indicated an increased cancer risk (hazard ratio 1.49) in users of tofacitinib, prompting warnings from the US Food and Drug Administration and European Medicines Agency [8]. Safety data have not been clear. Benucci et al. [9] found that JAK inhibitors generally have a good safety profile, suggesting that risk factors such as patient age, disease activity, smoking habits and comorbidities also play significant roles in cancer risk. A meta-analysis of 78 clinical trials and long-term studies indicated that JAK inhibitors are not associated with a higher incidence of malignancy compared with placebo or MTX, although a higher incidence is shown compared with TNF inhibitors [1]. Until further evidence emerges, caution and transdisciplinary counselling is advised when prescribing JAK inhibitors to patients with additional cancer risk factors. The rapid aging of the global population presents another critical challenge, with projections indicating a substantial increase in older age groups by 2050. RA cases peaked in the 75- to 79-year age group in 2020 and are expected to increase by 80% by 2050 [3]. Cancer follows a similar trajectory, with annual cases projected to increase by 77% from the current 20 million new diagnoses and 10 million deaths. Shared risk factors such as smoking, alcohol, infections and pollution contribute to both autoimmune rheumatic diseases and malignancies, with epidemiological data confirming a bidirectional link. In a cohort of 11 262 individuals (2011–2014), cancer patients (n = 826) had a significantly higher RA prevalence than those without cancer (9.0% vs 3.6%; P < 0.0001), with a mean age of 61 vs 44 years (P < 0.0001) [10]. Managing onco-rheumatologic patients remains a significant challenge due to the complexity of their conditions, which demands a comprehensive transdisciplinary approach. This concept of transdisciplinarity, where knowledge from various disciplines is integrated to create new frameworks, is crucial for addressing their multifaceted needs. The goal is not just achieve short-term results but to ensure long-term patient well-being as their conditions evolve. How can we, as healthcare professionals, ensure these patients receive the comprehensive care they need? Ongoing communication and synergy between specialists are key. This coordinated effort has led to the establishment of the Group of Multidimensional Onco-RhEumatology (G-MORE). It was established as a foundation for onco-rheumatologic collaboration by the Onco-Rheumatology Study Group of the CREI Executive Board (Italian College of Rheumatology) during its 18–20 July 2024 meeting. Its goal is to support scientific societies in further investigating this field and to foster a robust scientific dialogue among physicians. Through this collaborative approach, we aim to support the advancement of a more integrated, patient-centred care. No new data were generated or analysed for this editorial. D.M., C.M., P.M., A.F., P.A., G.B., G.C., A.F., T.F., F.G., G.I., M.C.M., L.M., L.P. and A.G. all contributed significantly to the work. D.M., C.M., L.P. and A.G. took lead roles in conceptualization, project administration and writing. A.F., P.A. and G.B. were instrumental in reviewing and analysis. G.C., A.F. and T.F. contributed to the methodology and design. F.G., G.I. and M.C.M. provided critical revisions of the manuscript for important intellectual content. L.M., A.G. and L.P. handled supervision and last critical revisions. No specific funding was received from any bodies in the public, commercial or not-for-profit sectors to carry out the work described in this article. Disclosure statement: The authors have declared no conflicts of interest.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.016
metaresearch head score (Gemma)0.046
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: Not applicable
GenreCandidate signal: Editorial · Consensus signal: Editorial
Teacher disagreement score0.018
Threshold uncertainty score0.082

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0160.046
Meta-epidemiology (narrow)0.0040.001
Meta-epidemiology (broad)0.0050.003
Bibliometrics0.0040.002
Science and technology studies0.0030.004
Scholarly communication0.0130.008
Open science0.0040.003
Research integrity0.0180.029
Insufficient payload (model declined to judge)0.0120.009

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.006
GPT teacher head0.344
Teacher spread0.338 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNot applicable
Domainnot available
GenreEditorial

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2025
Admission routes1
Has abstractno

Explore more

Same venueRheumatology Advances in Practice→Same topicRheumatoid Arthritis Research and Therapies→French-language works237,207→